Epidemiology, radiology and histology of atypical femoral fractures

Acta Orthopaedica

Volumn 84, Issue SUPPL. 352, 2013, Pages 1-26

  Schilcher, Jörg ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

ARTICLE; ATHLETE; ATYPICAL FEMORAL FRACTURE; BONE BIOPSY; BONE DENSITY; BONE MATRIX; BONE MINERALIZATION; BONE RADIOGRAPHY; BONE REMODELING; BONE TURNOVER; COHORT ANALYSIS; DRUG USE; FEMUR FRACTURE; FEMUR SHAFT FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; FRACTURE HEALING; HEALING IMPAIRMENT; HISTOLOGY; HUMAN; HYPOPHOSPHATASIA; MICRO-COMPUTED TOMOGRAPHY; MUSCULOSKELETAL FUNCTION; NECROSIS; OSTEOBLAST; OSTEOCLAST; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PAGET BONE DISEASE; RISK ASSESSMENT; STRESS FRACTURE; SWEDEN; CHEMICALLY INDUCED; DRUG EFFECTS; FEMORAL FRACTURES; PATHOLOGY; PATHOPHYSIOLOGY; RADIOGRAPHY;

BONE REMODELING; DIPHOSPHONATES; FEMORAL FRACTURES; FRACTURES, STRESS; HUMANS; OSTEOPOROSIS;

EID: 84890305008     PISSN: 17453674     EISSN: 17453682     Source Type: Journal    
DOI: 10.3109/17453674.2013.850008     Document Type: Article

References (87)

1. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: A register-based national cohort study. J Bone Miner Res 2009; 24(6): 1095-102.
2. Abrahamsen B B. Atypical femur fractures: refining the clinical picture. J Bone Miner Res 2012; 27(5): 975-6.
3. Allen M R, Burr D B. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: What we think we know and what we know that we don't know. Bone 2011; 49(1): 56-65.
4. Allen M R, Iwata K, Phipps R, Burr D B. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006; 39(4): 872-9. (Pubitemid 44311727)
5. Allen M R, Kubek D J, Burr D B. Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. J Bone Miner Res 2009; 25(1): 98-105.
6. Aspenberg P, Schilcher J, Fahlgren A. Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Acta Orthop 2010; 81(4): 460-2.
7. Bala Y, Farlay D, Chapurlat R D, Boivin G. Modifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronate. Eur J Endocrinol 2011; 165(4): 647-55.
8. Bennell K L, Malcolm S A, Wark J D, Brukner P D. Models for the pathogenesis of stress fractures in athletes. Br J Sports Med 1996; 30(3): 200-4. (Pubitemid 26326573)
9. Bieglmayer C, Dimai HP, Gasser RW, Kudlacek S, Obermayer-Pietsch B, Woloszczuk W, et al. Biomarker des Knochenumbaus in Diagnose und Therapie der Osteoporose. Wien Med Wochenschr 2012; 162(21-22): 464-77.
10. Black D M, Delmas P D, Eastell R, Reid I R, Boonen S, Cauley J A, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356(18): 1809-22. (Pubitemid 46698462)
11. Black D M, Kelly M P, Genant H K, Palermo L, Eastell R, Bucci-Rechtweg C, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. New England Journal of Medicine. Mass Medical Soc; 2010; 362(19): 1761-71.
12. Black D M, Reid I R, Boonen S, Bucci-Rechtweg C, Cauley J A, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012; 27(2): 243-54.
13. Black D M, Schwartz A V, Ensrud K E, Cauley J A, Levis S, Quandt S A, et al. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA: The Journal of the American Medical Association 2006; 296(24): 2927-38. (Pubitemid 46021497)
14. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000; 85(11): 4118-24. (Pubitemid 32055362)
15. Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 2000; 85(2): 720-6. (Pubitemid 32273660)
16. Bone HG, Hosking D, Devogelaer J-P, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350(12): 1189-99. (Pubitemid 38339363)
17. Boskey A L, Spevak L, Weinstein RS. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int 2008; 20(5): 793-800.
18. Burr D B. Targeted and nontargeted remodeling. Bone 2002; 30(1): 2-4. (Pubitemid 34044293)
19. Burr D B, Turner C H, Naick P, Forwood M R, Ambrosius W, Sayeed Hasan M, et al. Does microdamage accumulation affect the mechanical properties of bone J Biomech 1998; 31(4): 337-45. (Pubitemid 28322908)
20. Burr D B D, Forwood M R M, Fyhrie D P D, Martin R B R, Schaffler M B M, Turner C H C. Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res 1996; 12(1): 6-15.
21. Cardoso L, Herman B C, Verborgt O, Laudier D, Majeska R J, Schaffler M B. Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res 2009; 24(4): 597-605.
22. Chavassieux P M P, Arlot M E M, Reda C C, Wei L L, Yates A J A, Meunier P J P. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997; 100(6): 1475-80.
23. Cummings S R. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA: The Journal of the American Medical Association. 1998; 280(24): 2077-82. (Pubitemid 29014065)
24. Dell R, Greene D, Tran D. Stopping bisphosphonate treatment decreases the risk of having a second atypical femur fracture. 2012 AAOS Annual Meeting Abstract. http://www.aaos-annualmeeting-presskit.org/2012/clinicalpressreleases/ osteoporosis.shtml
25. Dell R M, Adams AL, Greene D F, Funahashi T T, Silverman S L, Eisemon E O, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012; 27(12): 2544-50.
26. Delmas P D, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 2004; 34(4): 599-604. (Pubitemid 38393794)
27. Demiralp B, Ilgan S, Ozgur Karacalioglu A, Cicek EI, Yildrim D, Erler K. Bilateral femoral insuffiency fractures treated with inflatable intramedullary nails: a case report. Arch Orthop Trauma Surg 2007; 127(7): 597-601. (Pubitemid 47226177)
28. Dencker H M. Fractures of the shaft of the femur. A clinical study based on 1003 fractures treated in Swedish hospitals during the three-year period 1952 to 1954. Thesis. Pp.1-135. University of Gothenburg; 1963.
29. Diab T, Condon K W, Burr D B, Vashishth D. Age-related change in the damage morphology of human cortical bone and its role in bone fragility. Bone 2006; 38(3): 427-31. (Pubitemid 43255437)
30. Donnelly E, Meredith D S, Nguyen J T, Boskey A L. Bone tissue composition varies across anatomic sites in the proximal femur and the iliac crest. J Orthop Res 2011; 30(5): 700-6.
31. Donnelly E, Meredith D S, Nguyen J T, Gladnick B P, Rebolledo B J, Shaffer A D, et al. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res 2012; 27(3): 672-8.
32. Ettinger B, Burr D B, Ritchie R O. Proposed pathogenesis for atypical femoral fractures: Lessons from materials research. Bone 2013; 55(2): 495-500.
33. Fågelberg E, Grassi L, Aspenberg P, Isaksson H. Can widening of a stress fracture decrease local strains sufficiently to enable healing Accepted conference abstract. In: European Society of Biomechanics, Patras, Greece; 2013 pp. 1-1.
34. Feldstein A C, Black D D, Perrin N N, Rosales A G A, Friess D D, Boardman D D, et al. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res 2012; 27(5): 977-86.
35. Follet H, Viguet-Carrin S, Burt-Pichat B, Depalle B, Bala Y, Gineyts E, et al. Effects of preexisting microdamage, collagen cross-links, degree of mineralization, age, and architecture on compressive mechanical properties of elderly human vertebral trabecular bone. J Orthop Res 2010; 29(4): 481-8.
36. Follet H H, Li J J, Phipps R J R, Hui S S, Condon K K, Burr D B D. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone 2007; 40(4): 6-6.
37. Fratzl P, Roschger P, Fratzl-Zelman N, Paschalis E P, Phipps R, Klaushofer K. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume. Calcif Tissue Int 2007; 81(2): 73-80. (Pubitemid 47240833)
38. Frost H M. Transient-steady state phenomena in microdamage physiology: a proposed algorithm for lamellar bone. Calcif Tissue Int 1989; 44(6): 367-81. (Pubitemid 19146906)
39. Frost H M. A brief review for orthopedic surgeons: fatigue damage (microdamage) in bone (its determinants and clinical implications). J Orthop Sci 1998; 3(5): 272-81. (Pubitemid 28455222)
40. Girgis C M, Sher D, Seibel M J. Atypical femoral fractures and bisphosphonate use. N Engl J Med 2010; 362(19): 1848-9.
41. Giusti A, Hamdy N A T, Papapoulos S E. Atypical fractures of the femur and bisphosphonate therapy. Bone 2010; 47(2): 169-80.
42. Goh S-K, Yang K Y, Koh J S B, Wong M K, Chua S Y, Chua D T C, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007; 89(3): 349-53. (Pubitemid 46563912)
43. Gourion-Arsiquaud S, Faibish D, Myers E, Spevak L, Compston J, Hodsman A, et al. Use of FTIR spectroscopic imaging to identify parameters associated with fragility fracture. J Bone Miner Res 2009; 24(9): 1565-71.
44. Güerri-Fernández R C, Nogués X, Quesada Gómez J M, Torres Del Pliego E, Puig L, García-Giralt N, et al. Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls. J Bone Miner Res 2013; 28(1): 162-8.
45. Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R. Lowenergy femoral fractures associated with the long-term use of bisphosphonates. Drug Saf 2009; 32(9): 775-85.
46. Johnell O, Kanis J A, Oden A, Johansson H, De Laet C, Delmas P, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20(7): 1185-94. (Pubitemid 40863806)
47. Kidd L J, Cowling N R, Wu A C K, Kelly W L, Forwood M R. Bisphosphonate treatment delays stress fracture remodeling in the rat ulna. J Orthop Res 2011; 29(12): 1827-33.
48. Koeppen V A, Schilcher J, Aspenberg P. Atypical fractures do not have a thicker cortex. Osteoporos Int 2012; 23(12): 2893-6.
49. Komatsubara S S, Mori S S, Mashiba T T, Ito M M, Li J J, Kaji Y Y, et al. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 2003; 18(3): 512-20.
50. Lenart B A, Lorich D G, Lane J M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008; 358(12): 1304-6. (Pubitemid 351439247)
51. Li J, Mashiba T, Burr D B. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001; 69(5): 281-6. (Pubitemid 33140938)
52. Mackie P S, Fisher J L, Zhou H, Choong P F. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 2001; 84(7): 951-8. (Pubitemid 32385839)
53. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312(7041): 1254-9. (Pubitemid 26147662)
54. Mashiba T, Dell RM, Mori S, Adams AL, Burr DB, Greene DF, et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005; 23 Suppl: 36-42.
55. Mashiba T, Turner C H, Hirano T, Forwood M R, Johnston C C, Burr D B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28(5): 524-31. (Pubitemid 32416465)
56. Mashiba T T, Hirano T T, Turner C H C, Forwood M R M, Johnston C C C, Burr D B D. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000; 15(4): 613-20.
57. Meijer W M, Penning-van Beest F J A, Olson M, Herings R M C. Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures. Curr Med Res Opin 2008; 24(11): 3217-22.
58. Mellstrom D D, Sörensen O H, Goemaere S, Roux C, Johnson T D, Chines A A. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75(6): 462-8. (Pubitemid 40174503)
59. Miller L M, Little W, Schirmer A, Sheik F, Busa B, Judex S. Accretion of bone quantity and quality in the developing mouse skeleton. J Bone Miner Res 2007; 22(7): 1037-45. (Pubitemid 351339726)
60. Neviaser A S, Lane J M, Lenart B A, Edobor-Osula F, Lorich D G. Lowenergy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008; 22(5): 346-50. (Pubitemid 351630250)
61. Norman TL, Wang Z. Microdamage of human cortical bone: incidence and morphology in long bones. Bone 1997; 20(4): 375-9. (Pubitemid 27196661)
62. Odvina C V, Zerwekh J E, Rao D S, Maalouf N, Gottschalk F A, Pak C Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90(3): 1294-301. (Pubitemid 40463979)
63. Perren S M. Physical and biological aspects of fracture healing with special reference to internal fixation. Clin Orthop Relat Res 1979; (138): 175-96. (Pubitemid 9199097)
64. Renders G A P, Mulder L, van Ruijven L J, Langenbach G E J, van Eijden T M G J. Mineral heterogeneity affects predictions of intratrabecular stress and strain. J Biomech 2011; 44(3): 402-7.
65. Rydholm A. Highly different risk estimates for atypical femoral fracture with use of bisphosphonates-debate must be allowed! Acta Orthop 2012; 83(4): 319-20.
66. Sahni M, Guenther H L, Fleisch H, Collin P, Martin T J. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993; 91(5): 2004-11. (Pubitemid 23141472)
67. Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 2009; 80(4): 413-5.
68. Schilcher J, Koeppen V, Ranstam J, Skripitz R, Michaëlsson K, Aspenberg P. Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls. Bone 2013; 52(1): 389-92.
69. Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364(18): 1728-37.
70. Schindeler A, Little D G. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro. Biochem Biophys Res Commun 2005; 338(2): 710-6. (Pubitemid 41597701)
71. Schneider J P. Should bisphosphonates be continued indefinitely An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2006; 61(1): 31-3. (Pubitemid 43134037)
72. Shane E, Burr D, Abrahamsen B, Adler R A, Brown T D, Cheung A M, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral research. J Bone Miner Res 2013 May 28. doi: 10.1002/jbmr.1998. [Epub ahead of print].
73. Shane E, Burr D, Ebeling P R, Abrahamsen B, Adler R A, Brown T D, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25(11): 2267-94.
74. Sloan A V, Martin J R, Li S, Li J. Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair. Bone 2010; 47(2): 235-40.
75. Smith S Y, Recker R R, Hannan M, Müller R, Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 2003; 32(1): 45-55. (Pubitemid 36173811)
76. Somford M P, Draijer F W, Thomassen B J, Chavassieux P M, Boivin G, Papapoulos S E. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: Clues to the mechanism of increased bone fragility. J Bone Miner Res 2009; 24(10): 1736-40.
77. Tai K, Dao M, Suresh S, Palazoglu A, Ortiz C. Nanoscale heterogeneity promotes energy dissipation in bone. Nat Mater 2007; 6(6): 454-62. (Pubitemid 46869995)
78. Tan S C, Koh S B J, Goh S K, Howe T S. Atypical femoral stress fractures in bisphosphonate-free patients. Osteoporos Int 2010; 22(7): 2211-2.
79. Tang S Y, Allen M R, Phipps R, Burr D B, Vashishth D. Changes in nonenzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 2009; 20(6): 887-94.
80. Tjhia C K, Odvina C V, Rao D S, Stover S M, Wang X, Fyhrie D P. Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects. Bone 2011; 49(6): 1279-89.
81. Valcourt U, Merle B, Gineyts E, Viguet-Carrin S, Delmas P D, Garnero P. Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. J Biol Chem 2007; 282(8): 5691-703. (Pubitemid 47093757)
82. Vashishth D, Behiri J C, Bonfield W. Crack growth resistance in cortical bone: concept of microcrack toughening. J Biomech 1997; 30(8): 763-9. (Pubitemid 27309599)
83. Vashishth D, Gibson G J, Khoury J I, Schaffler M B, Kimura J, Fyhrie D P. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 2001; 28(2): 195-201. (Pubitemid 32140975)
84. Viereck V, Emons G, Lauck V, Frosch K-H, Blaschke S, Gründker C, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002; 291(3): 7-7.
85. Weinstein R S, Roberson P K, Manolagas S C. Giant osteoclast formation and long-term oral bisphosphonate therapy. New Engl J Med 2009; 360(1): 53-62.
86. Yamagami Y, Mashiba T, Iwata K, Tanaka M, Nozaki K, Yamamoto T. Effects of minodronic acid and alendronate on bone remodeling, microdamage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys. Bone 2013; 54(1): 1-7.
87. Yu W, Glüer C C, Fuerst T, Grampp S, Li J, Lu Y, et al. Influence of degenerative joint disease on spinal bone mineral measurements in postmenopausal women. Calcif Tissue Int 1995; 57(3): 169-74.